Evidence map›Paper›PMID 36190661›Full record

ReviewDrug delivery and translational research2023

Nanocarriers for cancer nano-immunotherapy.

Isra Rana, Jaeeun Oh, Juwon Baig, Jeong Hyun Moon, Sejin Son, Jutaek Nam

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
  17. Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Isra RanaCollege of Pharmacy, Chonnam National University, Gwangju, 61186, South Korea.
Jaeeun OhDepartment of Biological Sciences, Inha University, Incheon, 22212, South Korea.
Juwon BaigDepartment of Biological Sciences, Inha University, Incheon, 22212, South Korea.
Jeong Hyun MoonDepartment of Biological Sciences, Inha University, Incheon, 22212, South Korea.
Sejin SonDepartment of Biological Sciences, Inha University, Incheon, 22212, South Korea. ssejin@inha.ac.kr.
Jutaek NamCollege of Pharmacy, Chonnam National University, Gwangju, 61186, South Korea. namj@jnu.ac.kr.ORCID http://orcid.org/0000-0002-0397-1449
Inha University · KRChonnam National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The host immune system possesses an intrinsic ability to target and kill cancer cells in a specific and adaptable manner that can be further enhanced by cancer immunotherapy, which aims to train the immune system to boost the antitumor immune response. Several different categories of cancer immunotherapy have emerged as new standard cancer therapies in the clinic, including cancer vaccines, immune checkpoint inhibitors, adoptive T cell therapy, and oncolytic virus therapy. Despite the remarkable survival benefit for a subset of patients, the low response rate and immunotoxicity remain the major challenges for current cancer immunotherapy. Over the last few decades, nanomedicine has been intensively investigated with great enthusiasm, leading to marked advancements in nanoparticle platforms and nanoengineering technology. Advances in nanomedicine and immunotherapy have also led to the emergence of a nascent research field of nano-immunotherapy, which aims to realize the full therapeutic potential of immunotherapy with the aid of nanomedicine. In particular, nanocarriers present an exciting opportunity in immuno-oncology to boost the activity, increase specificity, decrease toxicity, and sustain the antitumor efficacy of immunological agents by potentiating immunostimulatory activity and favorably modulating pharmacological properties. This review discusses the potential of nanocarriers for cancer immunotherapy and introduces preclinical studies designed to improve clinical cancer immunotherapy modalities using nanocarrier-based engineering approaches. It also discusses the potential of nanocarriers to address the challenges currently faced by immuno-oncology as well as the challenges for their translation to clinical applications.

Indexed as

NeoplasmsDrug CarriersHumansImmunotherapyNanomedicineDrug CarriersCancerDeliveryImmunotherapyNano-immunotherapyNanomedicineNanoparticle

Identifiers

PMID36190661
PMCPMC9528883
OpenAlexW4300690180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.